Study questions certain breast cancer treatment
November 09, 2017 04:54 AM
Patients with estrogen receptor positive breast cancer typically are treated with either tamoxifen or aromatase inhibitors for five years after their cancer treatment finishes.
But a new study suggests that may not be long enough. Researchers at the University of Michigan looked at women with ER positive breast cancer. They found those who originally had large tumors had up to a 40 percent chance of a recurrence 20 years later.
Experts say it could indicate patients might need to stay on tamoxifen or other medication longer than five years.
Created: November 09, 2017 04:54 AM
Copyright 2017 - WNYT-TV, LLC A Hubbard Broadcasting Company